Summary
An immunotoxin comprising a tumour-specific monoclonal antibody (11/160) coupled to ricin A chain, although inactive in in vitro cytotoxicity assays against HSNtc sarcoma target cells, was found to be capable of significant tumouricidal activity in syngeneic rats if potentiated by ricin B chain. The 11/160-ricin A, when bound to tumour cells prior to their inoculation, led to a slight inhibition of tumour growth s. c. compared with untreated sarcoma cells or those coated with antibody alone. However, all tumours in these groups developed progressively (69/69), whereas in those rats receiving 15 μ g or 150 μ g ricin B chain i. v. 5 min after tumour cell inoculation, the ‘take rate’ was reduced to 75% and 30% respectively, and significantly longer latent periods were evident for those tumours which did develop. Ricin B chain similarly inhibited, in a dose-dependent manner, the lung colonisation potential of 11/160-ricin A coated HSNtc cells. No effects were obtained if the B chain treatment followed inoculation of untreated or antibody-coated cells, suggesting that systemically administered B chain is capable of gaining access to and activating antibody-ricin A chain conjugates bound to the surface of syngeneic sarcoma cells in lung or subcutaneous sites. Tumour inhibition was obtained in some instances with intervals of up to 24 h between inoculation of conjugate-coated tumour cells and B chain. Experiments are in progress to determine if such potentiation may be feasible in a therapeutic rather than a prophylactic setting using this syngeneic solid tumour system.
Similar content being viewed by others
References
Bumol TF, Wang QC, Reisfeld RA, Kaplan NO (1983) Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumour growth. Proc Natl Acad Sci 80:529
Cushley W, Muirhead MJ, Silva F, Greathouse J, Tucker T, Uhr JW, Vitetta ES (1984) In vivo reconstitution of ricin-like activity from its A and B chain subunits. Toxicon 22:265
Dean CJ, Hobbs SM, Hopkins JV, North SM Styles JM (1982) Syngeneic antitumour antibodies in rats: clearance of cell bound antibody in vivo and in vitro. Br J Cancer 46:190
Eccles SA, Alexander P (1974) Macrophage content of tumours in relation to metastatic spread and host immune reaction. Nature 250:667
Eccles SA, Styles JM, Hobbs SM, Dean CJ (1979) Metastasis in the nude rat associated with lack of immune response. Br J Cancer 40:802
Funatsu G, Kumura M, Funatsu M (1979) Primary structure of A and B chains of ricin D Agric Biol Chem 43:221
Hwang KM, Foon KA, Cheung PH, Pearson JW, Oldham RK (1984) Selective anti-tumour effect on L10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and monoclonal antibody to a hepatoma associated antigen. Cancer Res 44:4578
Kishida K, Masuho Y, Saito M, Hara T, Fuji H (1983) Ricin A chain conjugated with anti-L1210 antibody. In vitro and in vivo anti-tumour activity. Cancer Immunol Immunother 16:93
Martinez O, Kimura J, Gottfried TD, Zeicher W, Wofsy L (1982) Variance in cytotoxic effectiveness of antibody-toxin A hybrids. Cancer Surv 1:373
McIntosh DP, Thorpe PE (1984) Role of the B chain in the cytotoxic action of antibody-ricin and antibody-abrin conjugates. In: Gregoriadis G, Poste G, Senior J, Touret A, (eds) Receptor-mediated targeting of drugs. Plenum Press, New York, London, p 105
McIntosh DP, Edwards DC, Cumber AJ, Parnell GD, Dean CJ, Ross WCJ, Forrester JA (1983) Ricin B converts a noncytotoxic antibody-ricin A chain conjugate into a potent and specific cytotoxic agent. FEBS Lett 164:17
North SM, Styles JM, Hobbs SM, Dean CJ (1982) Monoclonal antibodies to rat sarcomata. 1. Immunisation procedures and source of cells for hybridoma production. Immunology 47:397
Seto M, Unemoto N, Saito M, Masuho Y, Hara T, Takahashi T (1982) Monoclonal anti-MM46 antibody-ricin A chain conjugate: in vitro and in vivo antitumour activity. Cancer Res 42:5209
Thorpe PE, Ross WCJ (1982) The preparation and cytotoxic properties of antibody-toxin conjugates. Immunol Rev 62:119
Thorpe PE, Edwards DC, Ross WCJ, Davies AJS (1982) Monoclonal antibody-toxin conjugates: aiming the magic bullet. In: Fabre J, McMichael A (eds) Monoclonal antibodies in clinical medicine. Academic Press, London
Uhr WH (1982) Immunotoxins: harnessing Nature's poisons. J Immunol 133:1
Vitetta ES, Thorpe PE (1985) Immunotoxins containing ricin A or B chains with modified carbohydrate residues act synergistically in killing noeplastic B cells in vitro. Cancer Drug Delivery 2:191
Vitetta ES, Fulton RJ, Uhr JW (1984) Cytotoxicity of a cell-reactive immunoxin containing ricin A chain is potentiated by an anti-immunotoxin containing ricin B chain. J Exp Med 160:341
Youle RJ, Neville DM (1982) Kinetics of protein synthesis inactivation by ricin-anti-Thy 1.1 monoclonal antibody hybrids: role of the ricin B subunit demonstrated by reconstitution. J Biol Chem 257:1598
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eccles, S.A., McIntosh, D.P., Purvies, H.P. et al. An ineffective monoclonal antibody-ricin A chain conjugate is converted to a tumouricidal agent in vivo by subsequent systemic administration of ricin B chain. Cancer Immunol Immunother 24, 37–41 (1987). https://doi.org/10.1007/BF00199830
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00199830